291 related articles for article (PubMed ID: 18367997)
1. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).
Laron Z
Pediatr Endocrinol Rev; 2008 Mar; 5(3):766-71. PubMed ID: 18367997
[TBL] [Abstract][Full Text] [Related]
2. Long-term IGF-I treatment of children with Laron syndrome increases adiposity.
Laron Z; Ginsberg S; Lilos P; Arbiv M; Vaisman N
Growth Horm IGF Res; 2006 Feb; 16(1):61-4. PubMed ID: 16442822
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-I (lGF-l): safety and efficacy.
Laron Z
Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():78-85. PubMed ID: 16456486
[TBL] [Abstract][Full Text] [Related]
4. IGF-I replacement therapy in children with congenital IGF-I deficiency (Laron syndrome) maintains heart dimension and function.
Scheinowitz M; Feinberg MS; Laron Z
Growth Horm IGF Res; 2009 Jun; 19(3):280-2. PubMed ID: 19117781
[TBL] [Abstract][Full Text] [Related]
5. IGF-1 and insulin as growth hormones.
Laron Z
Novartis Found Symp; 2004; 262():56-77; discussion 77-83, 265-8. PubMed ID: 15562823
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone insensitivity syndrome (Laron syndrome): main characteristics and effects of IGF1 treatment.
Carel JC; Chaussain JL; Chatelain P; Savage MO
Diabetes Metab; 1996 Jul; 22(4):251-6. PubMed ID: 8767171
[TBL] [Abstract][Full Text] [Related]
7. Insulinlike growth factor I affects ocular development: a study of untreated and treated patients with Laron syndrome.
Bourla DH; Laron Z; Snir M; Lilos P; Weinberger D; Axer-Siegel R
Ophthalmology; 2006 Jul; 113(7):1197.e1-5. PubMed ID: 16815402
[TBL] [Abstract][Full Text] [Related]
8. Laron syndrome due to a post-receptor defect: response to IGF-I treatment.
Laron Z; Klinger B; Eshet R; Kaneti H; Karasik A; Silbergeld A
Isr J Med Sci; 1993 Dec; 29(12):757-63. PubMed ID: 8300382
[TBL] [Abstract][Full Text] [Related]
9. Consequences of not treating children with laron syndrome (primary growth hormone insensitivity).
Laron Z
J Pediatr Endocrinol Metab; 2001; 14 Suppl 5():1243-8; discussion 1261-2. PubMed ID: 11964019
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.
Kemp SF
BioDrugs; 2009; 23(3):155-63. PubMed ID: 19627167
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.
Chernausek SD; Backeljauw PF; Frane J; Kuntze J; Underwood LE;
J Clin Endocrinol Metab; 2007 Mar; 92(3):902-10. PubMed ID: 17192294
[TBL] [Abstract][Full Text] [Related]
12. Biphasic response of subscapular skinfold thickness to hGH or IGF-1 administration to patients with congenital IGHD, congenital MPHD and Laron syndrome.
Bisker-Kassif O; Kauli R; Lilos P; Laron Z
Obes Res Clin Pract; 2014; 8(1):e55-62. PubMed ID: 24548577
[TBL] [Abstract][Full Text] [Related]
13. Fifty seven years of follow-up of the Israeli cohort of Laron Syndrome patients-From discovery to treatment.
Laron Z; Kauli R
Growth Horm IGF Res; 2016 Jun; 28():53-6. PubMed ID: 26307357
[TBL] [Abstract][Full Text] [Related]
14. Clinical features and growth hormone receptor gene mutations of patients with Laron syndrome from a Chinese family.
Ying YQ; Wei H; Cao LZ; Lu JJ; Luo XP
Zhongguo Dang Dai Er Ke Za Zhi; 2007 Aug; 9(4):335-8. PubMed ID: 17706034
[TBL] [Abstract][Full Text] [Related]
15. Head circumference in untreated and IGF-I treated patients with Laron syndrome: comparison with untreated and hGH-treated children with isolated growth hormone deficiency.
Laron Z; Iluz M; Kauli R
Growth Horm IGF Res; 2012 Apr; 22(2):49-52. PubMed ID: 22414926
[TBL] [Abstract][Full Text] [Related]
16. Effect of insulin-like growth factor-1 deficiency or administration on the occurrence of acne.
Ben-Amitai D; Laron Z
J Eur Acad Dermatol Venereol; 2011 Aug; 25(8):950-4. PubMed ID: 21054577
[TBL] [Abstract][Full Text] [Related]
17. Do deficiencies in growth hormone and insulin-like growth factor-1 (IGF-1) shorten or prolong longevity?
Laron Z
Mech Ageing Dev; 2005 Feb; 126(2):305-7. PubMed ID: 15621211
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and therapeutic advances in growth hormone insensitivity.
David A; Metherell LA; Clark AJ; Camacho-Hübner C; Savage MO
Endocrinol Metab Clin North Am; 2005 Sep; 34(3):581-95, viii. PubMed ID: 16085161
[TBL] [Abstract][Full Text] [Related]
19. Statement 5: the first line of treatment for children with idiopathic short stature (ISS) and low serum insulin-like growth factor-I (IGF-I) should be IGF-I.
Backeljauw P
Pediatr Endocrinol Rev; 2008 Apr; 5 Suppl 3():853-6. PubMed ID: 18438329
[No Abstract] [Full Text] [Related]
20. Statement 6: patients who are unresponsive to GH therapy should be given a trial of IGF-I.
Hardin DS
Pediatr Endocrinol Rev; 2008 Apr; 5 Suppl 3():857-60. PubMed ID: 18438330
[No Abstract] [Full Text] [Related]
[Next] [New Search]
